Skip to main content
NTRB
NASDAQ Industrial Applications And Services

NutriBand Selects Commercial Brand Name for Lead Fentanyl Patch, Advancing Regulatory Path

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.811
Mkt Cap
$46.397M
52W Low
$3.42
52W High
$11.678
52W Position info
11% above low
Off High info
67% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

NTRB is trading near its 52-week low of $3.42 (11% above the low) on light trading volume (0.4× avg).

Summary

NutriBand Inc. has selected a commercial brand name for its lead abuse-deterrent fentanyl patch, a key milestone in its regulatory and commercialization strategy, with significant market potential.


Key Events · Product Development and Regulatory · NTRB

  • Commercial Brand Name Selected

    NutriBand Inc. has chosen a worldwide commercial brand name for its lead product, an abuse-deterrent fentanyl transdermal system, which utilizes its proprietary AVERSA™ technology.

  • Regulatory Submissions Initiated

    The selected brand name and product labeling will be submitted to the FDA and other international regulatory agencies for review and approval, alongside trademark registration with the United States Patent and Trademark Office (USPTO).

  • Significant Market Potential Identified

    The company estimates its abuse-deterrent fentanyl transdermal system has the potential to reach peak annual US sales of $80 million to $200 million.

  • Strategic Naming Partnership

    NutriBand partnered with Brand Institute, Inc., a global leader in pharmaceutical brand name development, and its regulatory subsidiary, Drug Safety Institute, to develop the brand name and ensure regulatory compliance.


Analysis · NTRB · Industrial Applications And Services

NutriBand's selection of a commercial brand name for its lead abuse-deterrent fentanyl patch marks a critical step towards regulatory approval and commercialization. For a company with a market capitalization of approximately $46 million, the projected peak annual US sales of $80 million to $200 million represent a potentially transformative opportunity. This development, supported by a partnership with a leading pharmaceutical branding firm, signals significant progress in bringing a high-value product to market and could substantially de-risk the company's future prospects.

At the time of this filing, NTRB was trading at $3.81 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $46.4M. The 52-week trading range was $3.42 to $11.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NTRB - Latest Insights

NTRB
Jun 22, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.24
Real-time Price: $2.96 info
Change: -$0.2849 (-9%) info
Market Cap: $35.921M info
NTRB
Jun 22, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.24
Real-time Price: $2.96 info
Change: -$0.2849 (-9%) info
Market Cap: $35.921M info
NTRB
Jun 11, 2026, 4:31 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $2.96 info
Change: -$0.565 (-16%) info
Market Cap: $35.921M info
NTRB
Jun 11, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $2.96 info
Change: -$0.565 (-16%) info
Market Cap: $35.921M info
NTRB
May 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.59
Real-time Price: $2.96 info
Change: -$0.635 (-18%) info
Market Cap: $35.921M info